These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19342997)

  • 1. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
    Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
    Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
    Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
    Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
    Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
    Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
    Falandry C; Brain E; Bonnefoy M; Mefti F; Jovenin N; Rigal O; Guillem O; El Kouri C; Uwer L; Abadie-Lacourtoisie S; Cretin J; Jacquin JP; Paraiso D; Freyer G
    Eur J Cancer; 2013 Sep; 49(13):2806-14. PubMed ID: 23735702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
    Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
    Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
    Grenader T; Goldberg A; Gabizon A
    Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
    Di Lorenzo G; Di Trolio R; Montesarchio V; Palmieri G; Nappa P; Delfino M; De Placido S; Dezube BJ
    Cancer; 2008 Mar; 112(5):1147-52. PubMed ID: 18098221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).
    Basso U; Roma A; Brunello A; Falci C; Fiduccia P; Banzato A; Bononi A; Gusella M; Vamvakas L; Zagonel V; Monfardini S
    J Geriatr Oncol; 2013 Oct; 4(4):340-5. PubMed ID: 24472477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.
    De Sanctis R; Bertuzzi A; Basso U; Comandone A; Marchetti S; Marrari A; Colombo P; Lutman RF; Giordano L; Santoro A
    Anticancer Res; 2015 Jan; 35(1):543-7. PubMed ID: 25550600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
    Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.